Does severe @entity417 caused by dose-dense @entity1311 - XXXX combination therapy have an effect on the survival of @entity1 with @entity43 ? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial.

@entity1 @entity43 @entity417 @entity3003 @entity1311 @entity40108
INTRODUCTION: To evaluate the incidence of @entity417 in @entity1 with @entity43 receiving @entity1311 - @entity3003 combination therapy ( @entity40108 ) using data from the Japanese Gynecologic Oncology Group (JGOG) 3016 trial, and to examine the effect of severe @entity417 on survival during dose-dense @entity40108 . METHODS: Retrospective analysis was conducted in @entity1 enrolled in the JGOG 3016 trial who underwent at least one cycle of the protocol therapy (n = 622). Hemoglobin values at enrollment and during each cycle of @entity40108 were collected. One-to-one matching was performed between @entity1 with and @entity1 without grade 3/4 @entity417 during @entity40108 ( @entity417 and nonanemia groups) to adjust the baseline characteristics of the @entity1 . The cumulative survival curve and median progression-free survival were estimated using the Kaplan-Meier method. RESULTS: Grades 2 to 4 @entity417 was observed in 19.8% of @entity1 before first-line @entity40108 . The incidence of grade 3/4 @entity417 rapidly increased to 56.1% after the fourth cycle of dose-dense @entity40108 . After matching, the median progression-free survival in the @entity417 (hemoglobin <8.0 g/dL) and nonanemia (hemoglobin >8.0 g/dL) groups was 777 and 1100 days, respectively (P = 0.3493) for @entity1 receiving dose-dense @entity40108 . The median progression-free survival in @entity1 receiving conventional @entity40108 was similar between the 2 groups. CONCLUSIONS: The difference in progression-free survival between @entity1 with @entity43 with and those without severe @entity417 during @entity40108 was not statistically significant, but for @entity1 receiving dose-dense @entity40108 , severe @entity417 seems to have prognostic relevance. Prospective trials are needed to investigate whether the optimal management of chemotherapy-induced @entity417 , including appropriate use of erythropoiesis-stimulating agents, would further improve the survival of @entity1 with @entity43 receiving dose-dense @entity40108 .
